Manufacturer of Controlled Substances; Notice of Registration; Cody Laboratories, Inc., 12103-12104 [2013-03881]

Download as PDF 12103 Federal Register / Vol. 78, No. 35 / Thursday, February 21, 2013 / Notices Drug Schedule erowe on DSK2VPTVN1PROD with NOTICES Aminorex (1585) ........................... Alpha-ethyltryptamine (7249) ....... Lysergic acid diethylamide (7315) Tetrahydrocannabinols (7370) ..... 4-Bromo-2,5dimethoxyamphetamine (7391). 4-Bromo-2,5dimethoxyphenethylamine (7392). 2,5-Dimethoxyamphetamine (7396). 3,4-Methylenedioxyamphetamine (7400). N-Hydroxy-3,4methylenedioxyamphetamine (7402). 3,4-Methylenedioxy-Nethylamphetamine (7404). 3,4Methylenedioxymethamphetamine (MDMA) (7405). Psilocybin (7437) .......................... 5-Methoxy-N,Ndiisopropyltryptamine (7439). 1-[1-(2Thienyl)cyclohexyl]piperidine (TCP) (7470). N-Benzylpiperazine (BZP) (7493) Heroin (9200) ............................... Normorphine (9313) ..................... Amphetamine (1100) .................... Methamphetamine (1105) ............ Nabilone (7379) ............................ 1-Phenylcyclohexylamine (7460) Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Ecgonine (9180) ........................... Levomethorphan (9210) ............... Levorphanol (9220) ...................... Meperidine (9230) ........................ Metazocine (9240) ........................ Methadone (9250) ........................ Morphine (9300) ........................... Thebaine (9333) ........................... Levo-alphacetylmethadol (9648) .. Remifentanil (9739) ...................... Carfentanil (9743) ......................... Fentanyl (9801) ............................ I I I I I 14:47 Feb 20, 2013 BILLING CODE 4410–09–P I DEPARTMENT OF JUSTICE I Drug Enforcement Administration I Manufacturer of Controlled Substances; Notice of Application; GE Healthcare I Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on August 31, 2012, GE Healthcare, 3350 North Ridge Avenue, Arlington Heights, Illinois 60004–1412, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Cocaine (9041), a basic class of controlled substance listed in schedule II. The company plans to manufacture a radioactive product to diagnose Parkinson’s disease; and to manufacture a bulk investigational new drug (IND) for clinical trials. Any other such applicant, and any person who is presently registered with DEA to manufacture such a substance, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 22, 2013. I I I I I I I I II II II II II II II II II II II II II II II II II II II Jkt 229001 Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug [FR Doc. 2013–03893 Filed 2–20–13; 8:45 am] The company plans to manufacture reference standards. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 22, 2013. VerDate Mar<15>2010 Dated: February 8, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. Dated: February 8, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–03895 Filed 2–20–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances, Notice of Application; Alltech Associates, Inc. Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on November 19, 2012, Alltech Associates Inc., 2051 Waukegan Road, Deerfield, Illinois 60015, made application to the Drug PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 5-Methoxy-N–Ndimethyltryptamine (7431). 2C–E (2-(2,5-Dimethoxy-4ethylphenyl)ethanamine) (7509). 2C–H (2-(2,5Dimethoxyphenyl)ethanamine) (7517). 2C–T–4 (2-(4-isopropylthio)-2,5dimethoxyphenyl) ethanamine) (7532). Schedule I I I I The company plans to manufacture high purity drug standards used for analytical applications only in clinical, toxicological, and forensic laboratories. Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than April 22, 2013. Dated: February 8, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–03919 Filed 2–20–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; Cody Laboratories, Inc. By Notice dated November 1, 2012, and published in the Federal Register on November 9, 2012, 77 FR 67398, Cody Laboratories, Inc., ATTN: Richard Asherman, 601 Yellowstone Avenue, Cody, Wyoming 82414, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: Drug Dihydromorphine (9145) ................ Amphetamine (1100) ...................... Methamphetamine (1105) .............. E:\FR\FM\21FEN1.SGM 21FEN1 Schedule I II II 12104 Federal Register / Vol. 78, No. 35 / Thursday, February 21, 2013 / Notices Schedule Drug Amobarbital (2125) ......................... Pentobarbital (2270) ....................... Secobarbital (2315) ........................ 4-Anilino-N-phenethyl-4-piperidine (ANPP) (8333). Phenylacetone (8501) .................... Cocaine (9041) ............................... Codeine (9050) .............................. Dihydrocodeine (9120) ................... Oxycodone (9143) .......................... Hydromorphone (9150) .................. Diphenoxylate (9170) ..................... Ecgonine (9180) ............................. Hydrocodone (9193) ...................... Meperidine (9230) .......................... Methadone (9250) .......................... Morphine (9300) ............................. Thebaine (9333) ............................. Oxymorphone (9652) ..................... Alfentanil (9737) ............................. Remifentanil (9739) ........................ Sufentanil (9740) ............................ Fentanyl (9801) .............................. II II II II II II II II II II II II II II II II II II II II II II Drug [FR Doc. 2013–03881 Filed 2–20–13; 8:45 am] BILLING CODE 4410–09–P erowe on DSK2VPTVN1PROD with NOTICES Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Registration; Cedarburg Pharmaceuticals, Inc. By Notice dated November 5, 2012, and published in the Federal Register 14:47 Feb 20, 2013 II II The company plans to manufacture the listed controlled substances in bulk for distribution to its customers. Regarding the drug code (8333), the company plans to use this controlled substance to manufacture another controlled substance. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Cedarburg Pharmaceuticals, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cedarburg Pharmaceuticals, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: February 8, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–03885 Filed 2–20–13; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Jkt 229001 Drug Enforcement Administration By Notice dated November 1, 2012, and published in the Federal Register on November 9, 2012, 77 FR 67398, InB Hauser Pharmaceutical Services, Inc., 6880 N. Broadway, Suite H, Denver, Colorado 80221, made application by letter to the Drug Enforcement PO 00000 Frm 00074 Fmt 4703 Sfmt 4703 Administration (DEA) to be registered as a bulk manufacturer of 4-Anilino-Nphenethyl-4-piperidine (8333), a basic class of controlled substance listed in schedule II. The company plans to manufacture the listed controlled substance in bulk for distribution and sale to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of InB Hauser Pharmaceutical Services, Inc., to manufacture the listed basic class of controlled substance is consistent with the public interest at this time. DEA has investigated InB Hauser Pharmaceutical Services, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems; verification of the company’s compliance with state and local laws; and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic class of controlled substance listed. Dated: February 8, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 2013–03886 Filed 2–20–13; 8:45 am] BILLING CODE 4410–09–P NATIONAL FOUNDATION ON THE ARTS AND THE HUMANITIES Proposed Collection of Information; Comment Request National Endowment for the Arts, National Foundation on the Arts and the Humanities. ACTION: Notice. Proposed collection; comment request. AGENCY: The National Endowment for the Arts (NEA), as part of its continuing effort to reduce paperwork and respondent burden, conducts a preclearance consultation program to provide the general public and federal agencies with an opportunity to comment on proposed and/or continuing collections of information in accordance with the Paperwork Reduction Act of 1995 (PRA95) [44 U.S.C. 3506(c)(A)]. This program helps to ensure that requested data can be provided in the desired format, reporting burden (time and financial SUMMARY: Manufacturer of Controlled Substances; Notice of Registration; INB Hauser Pharmaceutical Services, Inc. DEPARTMENT OF JUSTICE VerDate Mar<15>2010 Schedule 4-Anilino-N-phenethyl-4-piperidine ANPP) (8333). Fentanyl (9801) ............................ The company plans on manufacturing the listed controlled substances in bulk for sale to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a), and determined that the registration of Cody Laboratories, Inc., to manufacture the listed basic classes of controlled substances is consistent with the public interest at this time. DEA has investigated Cody Laboratories, Inc., to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the above named company is granted registration as a bulk manufacturer of the basic classes of controlled substances listed. Dated: February 8, 2013. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. on November 13, 2012, 77 FR 67676, Cedarburg Pharmaceuticals, Inc., 870 Badger Circle, Grafton, Wisconsin 53024, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances: E:\FR\FM\21FEN1.SGM 21FEN1

Agencies

[Federal Register Volume 78, Number 35 (Thursday, February 21, 2013)]
[Notices]
[Pages 12103-12104]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-03881]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Registration; 
Cody Laboratories, Inc.

    By Notice dated November 1, 2012, and published in the Federal 
Register on November 9, 2012, 77 FR 67398, Cody Laboratories, Inc., 
ATTN: Richard Asherman, 601 Yellowstone Avenue, Cody, Wyoming 82414, 
made application by renewal to the Drug Enforcement Administration 
(DEA) to be registered as a bulk manufacturer of the following basic 
classes of controlled substances:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
Dihydromorphine (9145)......................  I
Amphetamine (1100)..........................  II
Methamphetamine (1105)......................  II

[[Page 12104]]

 
Amobarbital (2125)..........................  II
Pentobarbital (2270)........................  II
Secobarbital (2315).........................  II
4-Anilino-N-phenethyl-4-piperidine (ANPP)     II
 (8333).
Phenylacetone (8501)........................  II
Cocaine (9041)..............................  II
Codeine (9050)..............................  II
Dihydrocodeine (9120).......................  II
Oxycodone (9143)............................  II
Hydromorphone (9150)........................  II
Diphenoxylate (9170)........................  II
Ecgonine (9180).............................  II
Hydrocodone (9193)..........................  II
Meperidine (9230)...........................  II
Methadone (9250)............................  II
Morphine (9300).............................  II
Thebaine (9333).............................  II
Oxymorphone (9652)..........................  II
Alfentanil (9737)...........................  II
Remifentanil (9739).........................  II
Sufentanil (9740)...........................  II
Fentanyl (9801).............................  II
------------------------------------------------------------------------

    The company plans on manufacturing the listed controlled substances 
in bulk for sale to its customers.
    No comments or objections have been received. DEA has considered 
the factors in 21 U.S.C. 823(a), and determined that the registration 
of Cody Laboratories, Inc., to manufacture the listed basic classes of 
controlled substances is consistent with the public interest at this 
time. DEA has investigated Cody Laboratories, Inc., to ensure that the 
company's registration is consistent with the public interest. The 
investigation has included inspection and testing of the company's 
physical security systems, verification of the company's compliance 
with state and local laws, and a review of the company's background and 
history.
    Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 
CFR 1301.33, the above named company is granted registration as a bulk 
manufacturer of the basic classes of controlled substances listed.

    Dated: February 8, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 2013-03881 Filed 2-20-13; 8:45 am]
BILLING CODE 4410-09-P